Divi’s Labs Q2 Review: Strong Performance Fails to Impress Motilal Oswal
Divi’s Labs Q2 Review: A Deep Dive into the Pharma Major’s Performance Divi’s Labs, one of India’s leading pharmaceutical companies, recently announced its Q2 results, which exceeded expectations. The company reported a 4% beat on revenue, 10% beat on Ebitda, and 10% beat on PAT. This strong performance was driven by its differentiated skill sets, […]